nach oben

Erschienen in:

15.02.2019 | Research Article

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

verfasst von: J. Corral, M. Majem, D. Rodríguez-Abreu, E. Carcereny, Á. A. Cortes, M. Llorente, J. M. López Picazo, Y. García, M. Domine, M P. López Criado

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Both nintedanib/docetaxel and anti‐PD‐1/PD‐L1 immunotherapies have demonstrated efficacy as second‐line treatment of patients with advanced lung adenocarcinoma. This is the first report on the efficacy of the nintedanib/docetaxel combination following first‐line platinum‐based chemotherapy and subsequent immunotherapy in a real-world setting.

Methods/patients

From May 2014 to December 2015, 390 patients in 108 Spanish centres enrolled in the nintedanib named patient use program. Inclusion criteria were advanced lung adenocarcinoma with progressive disease following at least one line of platinum‐based doublet chemotherapy. The objective was to evaluate the efficacy of the nintedanib/docetaxel combination in patients who also received immunotherapy.

Results

Eleven patients met the inclusion criteria; with a median age of 67 years. PD‐L1 expression was positive in six patients. Median progression‐free survival (PFS) of first‐line platinum‐based chemotherapy was 3.3 months (95% CI 1.9–4.6). Second‐line immunotherapy was pembrolizumab (36.5%), atezolizumab (36.5%) or nivolumab (27%). Median PFS of second‐line immunotherapy was 2.3 months (95% CI 0–6.1). The overall response rate (ORR) to second‐line immunotherapy was 18% with a disease‐control rate (DCR) of 45%. Median PFS of nintedanib/docetaxel was 3.2 months (95% CI 1.9–4.5). Best response was partial response in four patients (36%), stable disease in five patients (46%), and progressive disease in two patients (18%), for an ORR of 36% and a DCR of 82%.

Conclusion

Our experience suggests an encouraging efficacy of nintedanib/docetaxel in patients with adenocarcinoma NSCLC pretreated with platinum‐based doublet chemotherapy and immunotherapy, reinforcing the importance of an optimal therapeutic sequence for managing advanced lung adenocarcinoma.

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55. https://doi.org/10.1016/S1470-2045(13)70586-2.CrossRefPubMed

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73. https://doi.org/10.1016/S0140-6736(14)60845-X.CrossRefPubMed

Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study. Target Oncol. 2017;12(4):475–85. https://doi.org/10.1007/s11523-017-0517-2.CrossRefPubMed

Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, et al. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018;120:62–9. https://doi.org/10.1016/j.lungcan.2018.03.025.CrossRefPubMed

Reck M, Mellemgaard A, Novello S, Postmus PE, Gaschler-Markefski B, Kaiser R, et al. Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. Onco Targets Ther. 2018;11:4573–82. https://doi.org/10.2147/OTT.S170722.CrossRefPubMedPubMedCentral

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentral

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33. https://doi.org/10.1200/JCO.2017.74.3062.CrossRefPubMedPubMedCentral

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

10.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. https://doi.org/10.1016/S0140-6736(16)00587-0.CrossRefPubMed

11.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. https://doi.org/10.1016/S0140-6736(16)32517-X.CrossRefPubMed

12.

Commmitee for Medicinal Products for Human Use (CHMP). European Medicines Agency Assessment report of Opdivo. EMA/246304/2016. 2016.

13.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–26. https://doi.org/10.1056/NEJMoa1613493.CrossRefPubMedPubMedCentral

14.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. https://doi.org/10.1056/NEJMoa1801946.CrossRefPubMedPubMedCentral

15.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMed

16.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Version 1.2019—October 19, 2018.

17.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv192–237. https://doi.org/10.1093/annonc/mdy275.CrossRefPubMed

18.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.CrossRefPubMed

19.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–508. https://doi.org/10.1016/S1470-2045(16)30498-3.CrossRefPubMedPubMedCentral

20.

Lopes G, Wu Y-L, Kudaba I, Kowalski D, Cho BC, Castro G et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36(18_suppl):abstr LBA4. https://doi.org/10.1200/jco.2018.36.18_suppl.lba4.

21.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301. https://doi.org/10.1056/NEJMoa1716948.CrossRefPubMed

22.

Leger PD, Rothschild S, Castellanos E, Pillai RN, York SJ, Horn L. Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer. J Clin Oncol. 2017;35(15_suppl):abstr 9084. https://doi.org/10.1200/jco.2017.35.15_suppl.9084.

23.

Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017;112:90–5. https://doi.org/10.1016/j.lungcan.2017.07.034.CrossRefPubMed

24.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

25.

Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol. 2018;13(1):106–11. https://doi.org/10.1016/j.jtho.2017.10.011.CrossRefPubMed

26.

Grigg C, Reuland BD, Sacher AG, Yeh R, Rizvi NA, Shu CA. Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade. J Clin Oncol. 2017;35(15_suppl):abstr 9082. https://doi.org/10.1200/jco.2017.35.15_suppl.9082.

27.

Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csõszi T, Fülöp A et al. Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥ 50% enrolled in KEYNOTE-024. J Clin Oncol. 2017;35(15_suppl):abstr 9000. https://doi.org/10.1200/jco.2017.35.15_suppl.9000.

28.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, et al. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. ERJ Open Res. 2018. https://doi.org/10.1183/23120541.00120-2017.CrossRefPubMedPubMedCentral

29.

Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, et al. Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(6):831–9. https://doi.org/10.1016/j.jtho.2018.03.008.CrossRefPubMedPubMedCentral

30.

Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25. https://doi.org/10.1038/cdd.2013.67.CrossRefPubMed

31.

Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013;2(10):e27025. https://doi.org/10.4161/onci.27025.CrossRefPubMedPubMedCentral

32.

Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807. https://doi.org/10.1080/2162402X.2017.1331807.CrossRefPubMedPubMedCentral

33.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75. https://doi.org/10.1200/JCO.2009.26.7609.CrossRefPubMedPubMedCentral

34.

Hilberg F, Reschke M, Hofmann M, Kraut N. P2.01-045 Nintedanib improves anti-tumor efficacy in combination with anti PD-1 in syngeneic tumor models sensitive and refractory to IO inhibition. J Thorac Oncol. 2017;12(1):S813. abstr P2.01-045. https://doi.org/10.1016/j.jtho.2016.11.1097.

35.

Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55–63. https://doi.org/10.1016/j.coi.2015.01.011.CrossRefPubMedPubMedCentral

36.

Garde-Noguera J, Martin-Martorell P, De Julian M, Perez-Altozano J, Salvador-Coloma C, Garcia-Sanchez J, et al. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clin Transl Oncol. 2018;20(8):1072–9. https://doi.org/10.1007/s12094-017-1829-5.CrossRefPubMed

37.

Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781–9. https://doi.org/10.1200/JCO.2016.71.9476.CrossRefPubMedPubMedCentral

38.

Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521–36. https://doi.org/10.1016/S1470-2045(18)30144-X.CrossRefPubMedPubMedCentral

Titel: Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
verfasst von: J. Corral
M. Majem
D. Rodríguez-Abreu
E. Carcereny
Á. A. Cortes
M. Llorente
J. M. López Picazo
Y. García
M. Domine
M P. López Criado
Publikationsdatum: 15.02.2019
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 9/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02053-7

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Abstract

Purpose

Methods/patients

Results

Conclusion

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods/patients

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Differential expression of S1P receptor subtypes in human bladder transitional cell carcinoma

Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma

A candidate for lung cancer treatment: arsenic trioxide

Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells

Intraoperative blood loss does not independently affect the survival outcome of gastric cancer patients who underwent curative resection

Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie